Medicare Part D Payments for Transmucosal Immediate-Release Fentanyl Drugs

Transmucosal Immediate-Release Fentanyl (TIRF) drugs are a Schedule II controlled substance. Medicare Part D covers TIRF drugs only for managing breakthrough pain in adult cancer patients who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. We will determine whether TIRF drugs were appropriately dispensed in Medicare Part D in accordance with Medicare requirements.

Announced or Revised	Agency	Title	Component	Report Number(s)	Expected Issue Date (FY)
Completed	Centers for Medicare and Medicaid Services	Medicare Part D Payments for Transmucosal Immediate-Release Fentanyl Drugs	Office of Audit Services	W-00-20-35846; A-09-20-03033	2023